作者: C.M. Sommer , L. Pallwein-Prettner , D.F. Vollherbst , R. Seidel , C. Rieder
DOI: 10.1016/J.EJRAD.2016.10.024
关键词: Single Center 、 Radiology 、 Medicine 、 Percutaneous 、 Radiofrequency ablation 、 Renal cell carcinoma 、 Nephrectomy 、 Surgery 、 Embolization 、 Ablation 、 Microwave ablation
摘要: Percutaneous radiofrequency ablation (RFA) for the treatment of stage I renal cell carcinoma has recently gained significant attention as now available long-term and controlled data demonstrate that RFA can result in disease-free cancer-specific survival comparable with partial and/or radical nephrectomy. In non-controlled single center trials, however, rates failure vary. Operator experience technique may explain some different outcomes. a major limitation is lack adequate randomization. case reports, original series overview articles, transarterial embolization (TAE) before percutaneous was promising to increase tumor control reduce complications. The purpose this study systematically review literature on TAE add-on tumors. Specific regarding technique, patient characteristics well technical, clinical oncologic outcomes have been analyzed. Additionally, an state-of-the-art materials radiological perspective advanced image-guided (TA) will be discussed. conclusion, feasible very effective safe T1a tumors difficult locations T1b Advanced techniques technologies such microwave ablation, innovative software-based solutions are available, or near future, limitations bland RFA. Clinical implementation extremely important performing TA highly standardized procedure even most challenging cases localized